Seminars in Nuclear Medicine
Volume 36, Issue 2 , Pages 147-156 , April 2006

Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

  • Roelf Valkema, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
    • Corresponding Author InformationAddress reprint requests to Roelf Valkema, MD, Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
    • ,
  • Stanislas Pauwels, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium.
    • ,
  • Larry K. Kvols, MD, PhD

      Affiliations

    • GI Tumor Program, H. Lee Moffitt Cancer Hospital, University of Florida, Tampa, FL.
    • ,
  • Raffaella Barone, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium.
    • ,
  • Francois Jamar, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium.
    • ,
  • Willem H. Bakker, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
    • ,
  • Dik J. Kwekkeboom, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
    • ,
  • Hakim Bouterfa, PhD

      Affiliations

    • Novartis Pharmaceutical Corporation, East Hanover, NJ.
    • ,
  • Eric P. Krenning, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
    • Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.

References 

  1. Modlin IM , Lye KD , Kidd M . A 5-decade analysis of 13,715 carcinoid tumors . Cancer . 2003;97:934–959
  2. Jensen RT . Natural history of digestive endocrine tumors . In:  Mignon M ,  Colombel JF editor. Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors . Paris: John Libbey Eurotext; 1999;p. 192–219
  3. Arnold R , Simon B , Wied M . Treatment of neuroendocrine GEP tumours with somatostatin analogues (a review) . Digestion . 2000;62:84–91
  4. Faiss S , Pape UF , Bohmig M , et al.   Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group . J Clin Oncol . 2003;21:2689–2696
  5. Hejna M , Schmidinger M , Raderer M . The clinical role of somatostatin analogues as antineoplastic agents (Much ado about nothing?) . Ann Oncol . 2002;13:653–668
  6. Moertel CG , Hanley JA . Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome . Cancer Clin Trials . 1979;2:327–334
  7. Moertel CG , Hanley JA , Johnson LA . Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma . N Engl J Med . 1980;303:1189–1194
  8. Moertel CG , Lefkopoulo M , Lipsitz S , et al.   Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma . N Engl J Med . 1992;326:519–523
  9. Cheng PN , Saltz LB . Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma . Cancer . 1999;86:944–948
  10. De Vries H , Mulder NH , de Vries EG . Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma . (Letter) Cancer . 2000;88:2194–2195
  11. Moertel CG , Kvols LK , O’Connell MJ , et al.   Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms . Cancer . 1991;68:227–232
  12. Krenning EP , Kooij PP , Bakker WH , et al.   Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D- Phe1]-octreotide. A case history . Ann N Y Acad Sci . 1994;733:496–506
  13. Valkema R , De Jong M , Bakker WH , et al.   Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide (The Rotterdam experience) . Semin Nucl Med . 2002;32:110–122
  14. Anthony LB , Woltering EA , Espenan GD , et al.   Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies . Semin Nucl Med . 2002;32:123–132
  15. De Jong M , Bakker WH , Krenning EP , et al.   Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy . Eur J Nucl Med . 1997;24:368–371
  16. Albert R , Smith-Jones P , Stolz B , et al.   Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487) (Two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man) . Bioorg Med Chem Lett . 1998;8:1207–1210
  17. Kwekkeboom DJ , Mueller-Brand J , Paganelli G , et al.   Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs . J Nucl Med . 2005;46(suppl 1):62S–66S
  18. Smith MC , Liu J , Chen T , et al.   OctreoTher (ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy) . Digestion . 2000;62(suppl 1):69–72
  19. Valkema R , Pauwels S , Kvols LK , et al.   Long-term follow-up of a phase 1 study of peptide radionuclide therapy (PRRT) with [90Y-DOTA0,Tyr3]octreotide in patients with somatostatin receptor positive tumours . (Abstract) Eur J Nucl Med Mol Imaging . 2003;30:S232
  20. Jamar F , Barone R , Mathieu I , et al.   86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487)—a phase I clinical study (pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion) . Eur J Nucl Med Mol Imaging . 2003;30:510–518
  21. Green S , Weiss GR . Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria . Invest New Drugs . 1992;10:239–253
  22. Valkema R , Pauwels SA , Kvols LK , et al.   Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate . J Nucl Med . 2005;46(suppl 1):83S–91S
  23. Pauwels S , Barone R , Walrand S , et al.   Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs . J Nucl Med . 2005;46(suppl 1):92S–98S
  24. Barone R , Borson-Chazot F , Valkema R , et al.   Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC (relevance of kidney volume and dose rate in finding a dose-effect relationship) . J Nucl Med . 2005;46(suppl 1):99S–106S
  25. Bushnell D , O’Dorisio T , Menda Y , et al.   Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors . J Nucl Med . 2003;44:1556–1560
  26. Waldherr C , Pless M , Maecke HR , et al.   The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours (A clinical phase II study) . Ann Oncol . 2001;12:941–945
  27. Waldherr C , Pless M , Maecke HR , et al.   Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC . J Nucl Med . 2002;43:610–616
  28. Waldherr C , Schumacher T , Maecke HR , et al.   Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? . Eur J Nucl Med . 2002;29:S100
  29. Bodei L , Cremonesi M , Zoboli S , et al.   Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion (A phase I study) . Eur J Nucl Med Mol Imaging . 2003;30:207–216
  30. Moertel CG . Progress and hope in the treatment of gastrointestinal cancer . In:  Fortner JG ,  Rhoads JE editor. Accomplishments in Cancer Research 1987 . Philadelphia: Lippincott; 1988;p. 295–317
  31. Kvols LK , Reubi JC . Metastatic carcinoid tumors and the malignant carcinoid syndrome . Acta Oncol . 1993;32:197–201
  32. Kwekkeboom DJ , Teunissen JJ , Bakker WH , et al.   Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors . J Clin Oncol . 2005;23:2754–2762
  33. Teunissen JJ , Kwekkeboom DJ , Krenning EP . Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate . J Clin Oncol . 2004;22:2724–2729
  34. Sun W , Lipsitz S , Catalano P , et al.   Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors (Eastern Cooperative Oncology Group Study E1281) . J Clin Oncol . 2005;23:4897–4904
  35. Arnold R , Rinke A , Schmidt C , et al.   Chemotherapy . Best Pract Res Clin Gastroenterol . 2005;19:649–656
  36. Shah T , Caplin M . Biotherapy for metastatic endocrine tumours . Best Pract Res Clin Gastroenterol . 2005;19:617–636
  37. Quaedvlieg PF , Visser O , Lamers CB , et al.   Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients . Ann Oncol . 2001;12:1295–1300
  38. Krenning EP , Kwekkeboom DJ , Bakker WH , et al.   Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I- Tyr3]-octreotide (The Rotterdam experience with more than 1000 patients) . Eur J Nucl Med . 1993;20:716–731
  39. Gibril F , Reynolds JC , Doppman JL , et al.   Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study . Ann Intern Med . 1996;125:26–34
  40. Arnold R , Rinke A , Klose KJ , et al.   Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors (a randomized trial) . Clin Gastroenterol Hepatol . 2005;3:761–771

PII: S0001-2998(06)00002-X

doi: 10.1053/j.semnuclmed.2006.01.001

Seminars in Nuclear Medicine
Volume 36, Issue 2 , Pages 147-156 , April 2006

Article Tools

* Image Usage & Resolution